Your browser doesn't support javascript.
loading
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. Reply.
Garrelfs, Sander F; Gansner, John M; Lieske, John C.
Affiliation
  • Garrelfs SF; Emma Children's Hospital, Amsterdam, the Netherlands s.f.garrelfs@amsterdamumc.nl.
  • Gansner JM; Alnylam Pharmaceuticals, Cambridge, MA.
  • Lieske JC; Mayo Clinic, Rochester, MN.
N Engl J Med ; 385(20): e69, 2021 11 11.
Article in En | MEDLINE | ID: mdl-34758265
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hyperoxaluria, Primary / RNAi Therapeutics Limits: Humans Language: En Journal: N Engl J Med Year: 2021 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hyperoxaluria, Primary / RNAi Therapeutics Limits: Humans Language: En Journal: N Engl J Med Year: 2021 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos